Regorafenib Hydrochloride is primarily used in the treatment of certain types of cancer. It is specifically indicated for patients with metastatic colorectal cancer who have previously been treated with other therapies. Additionally, it is used for advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have stopped responding to other treatments. The drug is also approved for hepatocellular carcinoma (HCC), a type of liver cancer, in patients who have previously been treated with sorafenib.

The compound works by inhibiting multiple kinase enzymes involved in tumor growth, angiogenesis, and the tumor microenvironment. This helps to slow down or stop the progression of cancer by blocking the signals that promote cancer cell proliferation and blood vessel formation.

Patients are typically administered this medication orally, and it is often used as part of a broader treatment plan that may include other therapies. Regular monitoring is essential to manage potential side effects, which can include fatigue, hand-foot skin reaction, hypertension, and gastrointestinal issues.